EMAN IBRAHİM ALY MAHMOUD, NEHAD MOHAMED SAYED ABDELFATTAH, SHEREEN EL SAYED MOHAMED TAHA, HANY MOHAMED ABDALLAH HEGAB, GAMAL MOHAMED FATHY, FATMA ELZAHRAA YOUSSEF FATHY
Turkish Journal of Immunology - 2025;13(2):80-89
Objective: Acute myeloid leukemia (AML) is a heterogeneous blood malignancy with wide genomic aberrations, treatment approaches, and treatment outcomes. Successful treatment for AML remains challenging. CD73 is a recently recognized immune checkpoint mediator that is highly expressed in tumor microenvironment. It catalyzes the hydrolysis of adenosine monophosphate (AMP) to adenosine, which subsequently inhibits anti-tumor immune responses. This study aimed to investigate the relationship between CD73 and the response to induction therapy in adult Egyptian patients with AML. Materials and Methods: A total of 44 blood samples were collected from 25 patients. Each survivor of induction therapy provided two samples: one on the day of initial diagnosis and another on the day of assessment of response to induction therapy (ARIT). Patients who did not survive induction therapy provided only one sample on the day of diagnosis. CD73 was measured on T cells using flow cytometric analysis and correlated with the response to treatment. Results: Among the study cohort, median CD73 expression was 10.6% on T cells and 22.1% on CD8+ T cells. There was no statistically significant difference across different risk categories, nor was there an association with treatment response. However, CD73 expression showed a positive correlation with 28-day survival. Conclusion: CD73 expression did not show a significant relationship with any patient characteristics or disease parameters and did not affect treatment response. Nevertheless, it was positively correlated with 28-day survival.
